Skip to content

Study · Randomized controlled trial · n = 65 · 2008

21 results

Effects of an oral ghrelin mimetic on body composition and clinical outcomes in healthy older adults: a randomized trial.

Nass R, Pezzoli SS, Oliveri MC, Patrie JT, Harrell FE Jr, Clasey JL, Heymsfield SB, Bach MA, Vance ML, Thorner MO

Annals of internal medicine1 Nov 2008Cited by 176 (Europe PMC)

PMID18981485 (opens in a new tab)PMCIDPMC2757071 (opens in a new tab)DOI10.7326/0003-4819-149-9-200811040-00003 (opens in a new tab)PepBankPUB-18981485
Source linkPubMedAsk about this study
Jump to 21 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study21

21 results from studies that gave the peptide. 21 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, fat-free mass increased with MK‑677 and decreased with placebo.

    In plain wordsIn healthy older adults, fat-free mass increased with MK‑677 and decreased with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseFat-free mass
    Study

    n = 65

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Fat-free mass change
    −0.5 kg
    placebo
    Fat-free mass change
    1.1 kg
    MK-677
    P value
    < 0.001
    MK-677 versus placebo
    95% confidence interval for fat-free mass change
    −1.1 to 0.2 kg
    placebo
    Confidence interval for fat-free mass change
    0.7 to 1.5 kg
    MK-677

    Source sentences

    Summary
    Mean fat-free mass decreased in the placebo group but increased in the MK-677 group (change, -0.5 kg [95% CI, -1.1 to 0.2 kg] vs. 1.1 kg [CI, 0.7 to 1.5 kg], respectively; P < 0.001)
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, abdominal visceral fat did not differ significantly between MK‑677 and placebo.

    In plain wordsIn healthy older adults, abdominal visceral fat did not differ significantly between MK‑677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeAbdominal visceral fat
    Study

    n = 65

    Comparator
    Placebo
    Analysis
    Primary
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in abdominal visceral fat or total fat mass
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, intracellular water reflecting body cell mass increased with MK‑677 and decreased with placebo.

    In plain wordsIn healthy older adults, body cell mass increased with MK‑677 and decreased with placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseBody cell mass
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Intracellular water change
    −1 kg
    placebo
    Intracellular water change
    0.8 kg
    MK-677
    P value
    0.021
    MK-677 versus placebo
    Confidence interval for intracellular water change
    −2.1 to 0.2 kg
    placebo
    Confidence interval for intracellular water change
    −0.1 to 1.6 kg
    MK-677

    Source sentences

    Summary
    as did body cell mass, as reflected by intracellular water (change, -1.0 kg [CI, -2.1 to 0.2 kg] vs. 0.8 kg [CI, -0.1 to 1.6 kg], respectively; P = 0.021).
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, total fat mass did not differ significantly between MK‑677 and placebo.

    In plain wordsIn healthy older adults, total fat mass did not differ significantly between MK‑677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeTotal fat mass
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    No significant differences were observed in abdominal visceral fat or total fat mass
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, limb fat increased more with MK‑677 than placebo.

    In plain wordsIn healthy older adults, limb fat increased more with MK‑677 than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseLimb fat
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Limb fat increase
    0.24 kg
    placebo
    Limb fat increase
    1.1 kg
    MK-677
    P value
    0.001
    MK-677 versus placebo

    Source sentences

    Summary
    however, the average increase in limb fat was greater in the MK-677 group than the placebo group (1.1 kg vs. 0.24 kg; P = 0.001).
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, body weight increased more with MK‑677 than placebo.

    In plain wordsIn healthy older adults, body weight increased more with MK‑677 than placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseBody weight
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Body weight change
    0.8 kg
    placebo
    Body weight change
    2.7 kg
    MK-677
    P value
    0.003
    MK-677 versus placebo
    Confidence interval for body weight change
    −0.3 to 1.8 kg
    placebo
    Confidence interval for body weight change
    2 to 3.5 kg
    MK-677

    Source sentences

    Summary
    Body weight increased 0.8 kg (CI, -0.3 to 1.8 kg) in the placebo group and 2.7 kg (CI, 2.0 to 3.5 kg) in the MK-677 group (P = 0.003).
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  7. 07HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, total cholesterol did not differ between MK‑677 and placebo.

    In plain wordsIn healthy older adults, total cholesterol did not differ between MK‑677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeTotal cholesterol
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    no differences between groups were observed in total or high-density lipoprotein cholesterol levels.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  8. 08HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, HDL cholesterol did not differ between MK‑677 and placebo.

    In plain wordsIn healthy older adults, HDL cholesterol did not differ between MK‑677 and placebo.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeHDL cholesterol
    Study

    n = 65

    Comparator
    Placebo
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    no differences between groups were observed in total or high-density lipoprotein cholesterol levels.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  9. 09HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, MK‑677 increased growth hormone to healthy young-adult levels.

    In plain wordsIn healthy older adults, MK‑677 increased growth hormone to young-adult levels.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseGrowth hormone
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  10. 10HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, MK‑677 increased IGF-I to healthy young-adult levels.

    In plain wordsIn healthy older adults, MK‑677 increased IGF-I to young-adult levels.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIGF-I
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  11. 11HumanRandomized controlled trialSafety outcome

    In healthy older adults, daily MK‑677 was reported to cause no serious adverse effects.

    In plain wordsIn healthy older adults, MK‑677 treatment was reported without serious adverse effects.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableSerious adverse effects
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Daily administration of MK-677 significantly increased growth hormone and insulin-like growth factor I levels to those of healthy young adults without serious adverse effects.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  12. 12HumanRandomized controlled trialSafety outcome

    In healthy older adults, fasting glucose increased with MK‑677.

    In plain wordsIn healthy older adults, fasting glucose increased during MK‑677 treatment.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseFasting blood glucose
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Fasting blood glucose change
    0.3 mmol/L
    MK-677 group
    Fasting blood glucose change
    5 mg/dL
    MK-677 group
    P value
    0.015
    MK-677 group

    Source sentences

    Summary
    Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  13. 13HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, insulin sensitivity decreased with MK‑677.

    In plain wordsIn healthy older adults, insulin sensitivity decreased during MK‑677 treatment.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseInsulin sensitivity
    Study

    n: not reported in source

    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Fasting blood glucose level increased an average of 0.3 mmol/L (5 mg/dL) in the MK-677 group (P = 0.015), and insulin sensitivity decreased.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  14. 14HumanRandomized controlled trialSafety outcome

    In healthy older adults, increased appetite was a frequent MK‑677 side effect and subsided within a few months.

    In plain wordsIn healthy older adults, increased appetite was a frequent MK‑677 side effect that subsided within a few months.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseIncreased appetite
    Study

    n: not reported in source

    Outcome group
    Adverse events · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  15. 15HumanRandomized controlled trialSafety outcome

    In healthy older adults, transient mild lower-extremity edema was a frequent MK‑677 side effect.

    In plain wordsIn healthy older adults, temporary mild leg swelling was a frequent MK‑677 side effect.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableLower-extremity edema
    Study

    n: not reported in source

    Outcome group
    Adverse events · Whole body
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  16. 16HumanRandomized controlled trialSafety outcome

    In healthy older adults, muscle pain was a frequent MK‑677 side effect.

    In plain wordsIn healthy older adults, muscle pain was a frequent MK‑677 side effect.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Not applicableMuscle pain
    Study

    n: not reported in source

    Outcome group
    Pain · Musculoskeletal
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    The most frequent side effects were an increase in appetite that subsided in a few months and transient, mild lower-extremity edema and muscle pain.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  17. 17HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, LDL cholesterol decreased from baseline with MK‑677.

    In plain wordsIn healthy older adults, LDL cholesterol decreased from baseline with MK‑677.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    DecreaseLDL cholesterol
    Study

    n: not reported in source

    Comparator
    Baseline
    Outcome group
    Lipids · Metabolic and weight
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    LDL cholesterol change
    −0.14 mmol/L
    MK-677 group versus baseline
    LDL cholesterol change
    −5.4 mg/dL
    MK-677 group versus baseline
    P value
    0.026
    MK-677 group versus baseline
    Confidence interval for LDL cholesterol change (confidence level not stated)
    −0.27 to −0.01 mmol/L
    MK-677 group versus baseline
    Confidence interval for LDL cholesterol change (confidence level not stated)
    −10.4 to −0.4 mg/dL
    MK-677 group versus baseline

    Source sentences

    Summary
    Low-density lipoprotein cholesterol levels decreased in the MK-677 group relative to baseline values (change, -0.14 mmol/L [CI, -0.27 to -0.01 mmol/L]; -5.4 mg/dL [CI, -10.4 to -0.4 mg/dL]; P = 0.026)
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  18. 18HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, cortisol increased in MK‑677 recipients.

    In plain wordsIn healthy older adults, cortisol increased during MK‑677 treatment.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    IncreaseCortisol
    Study

    n: not reported in source

    Outcome group
    Stress hormones · Endocrine and hormones
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Measurements

    Cortisol increase
    47 nmol/L
    MK-677 recipients
    Cortisol increase
    1.7 microg/dL
    MK-677 recipients
    P value
    0.02
    MK-677 recipients
    Confidence interval for cortisol increase (confidence level not stated)
    28 to 71 nmol/L
    MK-677 recipients
    Confidence interval for cortisol increase (confidence level not stated)
    1 to 2.6 microg/dL
    MK-677 recipients

    Source sentences

    Summary
    Cortisol levels increased 47 nmol/L (CI, 28 to 71 nmol/L (1.7 microg/dL [CI, 1.0 to 2.6 microg/dL]) in MK-677 recipients (P = 0.020).
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  19. 19HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, MK‑677 recipients had bone mineral density changes consistent with increased bone remodeling.

    In plain wordsIn healthy older adults, bone density changes during MK‑677 treatment were consistent with increased bone remodeling.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    Direction not reportedBone mineral density
    Study

    n: not reported in source

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Changes in bone mineral density consistent with increased bone remodeling occurred in MK-677 recipients.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  20. 20HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, increased fat-free mass with MK‑677 did not produce changes in strength.

    In plain wordsIn healthy older adults, increased fat-free mass with MK‑677 did not change strength.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeStrength
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Increased fat-free mass did not result in changes in strength or function.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.
  21. 21HumanRandomized controlled trialEfficacy outcome

    In healthy older adults, increased fat-free mass with MK‑677 did not produce changes in function.

    In plain wordsIn healthy older adults, increased fat-free mass with MK‑677 did not change function.

    Peptide
    MK-677 (ibutamoren)
    Outcome
    No significant changeFunction
    Study

    n: not reported in source

    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    25 mg once daily · oral · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Increased fat-free mass did not result in changes in strength or function.
    3 context sentences
    Summary · context
    2-year, double-blind, randomized, placebo-controlled, modified-crossover clinical trial.
    Summary · context
    65 healthy adults (men, women receiving hormone replacement therapy, and women not receiving hormone replacement therapy) ranging from 60 to 81 years of age.
    Summary · context
    Oral administration of MK-677, 25 mg, or placebo once daily.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    14 Oct 2026, 05:02 UTC

    Study results updated

  2. Version 1

    14 Oct 2026, 01:46 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.